Company news
Halberd Corp. news in 2024
Halberd Corp.'s news releases, calls and decks from 2024, newest first.
Halberd Update on WatchDawg® PTSD Treatment
December 1, 2024
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
September 30, 2024
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
September 10, 2024
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
September 8, 2024
Halberd Corp. Issues Letter to Shareholders
August 25, 2024
Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
July 23, 2024
Halberd/Athena GTX Research Promises a Much Brighter Future
May 21, 2024
Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill
May 8, 2024
Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
April 29, 2024
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
April 3, 2024
Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing
February 7, 2024
Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast"
February 5, 2024
Halberd Corporation 2023 Year-End CEO Update and 2024 Goals
January 10, 2024
CORRECTION BY SOURCE: Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
January 9, 2024
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
January 8, 2024